News United Therapeutics Corporation

Equities

UTHR

US91307C1027

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 10/12/2025 GMT			5-day change	1st Jan Change
484.86 ^USD	+1.78%		+0.81%	+37.42%

12-10	United Therapeutics Insider Sold Shares Worth $3,833,374, According to a Recent SEC Filing	MT
12-09	United Therapeutics Insider Sold Shares Worth $10,050,597, According to a Recent SEC Filing	MT

United Therapeutics Insider Sold Shares Worth $3,833,374, According to a Recent SEC Filing	12-10	MT
United Therapeutics Insider Sold Shares Worth $10,050,597, According to a Recent SEC Filing	12-09	MT
United Therapeutics Insider Sold Shares Worth $3,870,056, According to a Recent SEC Filing	12-08	MT
United Therapeutics Insider Sold Shares Worth $3,821,130, According to a Recent SEC Filing	12-05	MT
United Therapeutics Insider Sold Shares Worth $10,798,079, According to a Recent SEC Filing	12-02	MT
United Therapeutics Insider Sold Shares Worth $3,852,846, According to a Recent SEC Filing	12-02	MT
United Therapeutics Insider Sold Shares Worth $10,079,696, According to a Recent SEC Filing	12-02	MT
United Therapeutics Insider Sold Shares Worth $3,784,419, According to a Recent SEC Filing	11-25	MT
United Therapeutics Insider Sold Shares Worth $3,812,082, According to a Recent SEC Filing	11-21	MT
United Therapeutics Insider Sold Shares Worth $3,789,373, According to a Recent SEC Filing	11-20	MT
United Therapeutics Corporation Presents at Jefferies London Healthcare Conference 2025, Nov-18-2025 12:00 PM	11-18
United Therapeutics Insider Sold Shares Worth $4,755,854, According to a Recent SEC Filing	11-14	MT
United Therapeutics Insider Sold Shares Worth $5,112,335, According to a Recent SEC Filing	11-13	MT
United Therapeutics Insider Sold Shares Worth $3,600,830, According to a Recent SEC Filing	11-12	MT
United Therapeutics Corporation Presents at UBS Global Healthcare Conference 2025, Nov-10-2025 09:30 AM	11-10
United Therapeutics Insider Sold Shares Worth $3,488,423, According to a Recent SEC Filing	11-06	MT
UBS Adjusts Price Target on United Therapeutics to $600 From $580, Maintains Buy Rating	11-06	MT
United Therapeutics Insider Sold Shares Worth $9,157,821, According to a Recent SEC Filing	11-05	MT
United Therapeutics Insider Sold Shares Worth $9,658,073, According to a Recent SEC Filing	11-04	MT
United Therapeutics Insider Sold Shares Worth $3,554,592, According to a Recent SEC Filing	11-04	MT
United Therapeutics Corporation to Present at Upcoming Investor Conferences	11-04	BU
First clinical trial of pig kidney transplants gets underway	11-03	AQ
United Therapeutics Corporation Announces First Transplant in Expands Clinical Trial of UKidney in Patients with End-Stage Renal Disease	11-03	CI
United Therapeutics Corporation Announces First Transplant in EXPAND Clinical Trial of UKidney in Patients With End-Stage Renal Disease	11-03	BU
United Therapeutics Insider Sold Shares Worth $3,538,949, According to a Recent SEC Filing	10-31	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

United Therapeutics delivers 18th consecutive quarter of topline growth

June 17, 2025 at 08:39 am